NCT04082520 2026-04-22
Lutathera for the Treatment of Inoperable, Progressive Meningioma After External Beam Radiation Therapy
Mayo Clinic
Phase 2 Recruiting
Clinical Trials
9 trialsNCT07150806 2026-04-17
RYZ101 for the Treatment of Progressive or Recurrent Intracranial Meningioma
Ohio State University Comprehensive Cancer Center
Phase 1/2 Suspended
NCT05691465 2026-04-13
Testing the Safety and Effectiveness of Radiation-based Treatment (Lutetium Lu 177 Dotatate) for Metastatic Prostate Cancer That Has Neuroendocrine Cells
National Cancer Institute (NCI)
Phase 2 Recruiting
NCT04040088 2026-03-31
An Investigational Scan (68Ga-DOTATATE PET/CT) in Diagnosing Pediatric Metastatic Neuroendocrine Tumors
Mayo Clinic
Phase EARLY_PHASE1 Active not recruiting
NCT07150546 2026-03-02
Combination External Radiation and PRRT for Large GI Neuroendocrine Tumors.
Emory University
Phase 1 Recruiting
NCT04529044 2025-10-30
177Lu-DOTATATE for the Treatment of Stage IV or Recurrent Breast Cancer
OHSU Knight Cancer Institute
Phase 2 Not yet recruiting
NCT04609592 2025-09-09
Study of PRRT in Metastatic, World Health Organization (WHO) Grade 1 or 2, SSTR Positive, GEP-NET Who Are Candidates for Cytoreductive Surgery
Stanford University
Phase 1 Recruiting
NCT03448458 2025-07-17
Gallium Ga 68-DOTATATE PET/CT in Diagnosing Patients With Metastatic Castration Resistant Prostate Cancer
Emory University
Phase 2 Completed
NCT06091748 2025-06-03
Gallium (68Ga) Edotreotide PET/CT for Imaging Patients With Gastrointestinal Pancreatic Neuroendocrine Tumors
Jiangsu HengRui Medicine Co., Ltd.
Phase 3 Recruiting